Eikon Therapeutics, Inc. EIKN Operating lease liabilities

Operating lease liabilities at other companies

iRhythm Holdings, Inc. IRTC

-$2.7M-22.4%

ZymeworksZYME

-$1.01M-23.5%

Fastly, Inc. FSLY

-$5.81M-4.6%

EPAM SystemsEPAM

-$9.64M+12.1%

PBH

Prestige Consumer HealthcarePBH

-$2M-4.7%

Sherwin-WilliamsSHW

-$118.7M+4.4%

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Market cap$521.35M—

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Eikon Therapeutics, Inc. 's operating lease liabilities?: Eikon Therapeutics, Inc. (EIKN) reported operating lease liabilities of -$2.49M in Q1 2026.